Standalone Performance Highlights: Q4 FY2021:
- Total income of Rs144cr, growth of 9.3% on qoq and 24.1% on yoy basis
- Operating EBITDA of Rs34.6cr with EBITDA margins of 24.0%
- Net profit stood at Rs11cr with margins of 7.7%
- Net cash up by Rs55.7cr over March 2020
- Number of surgeries performed were 5,472, growth of 77.5% on qoq basis
- Bed occupied during the quarter were 481 as compared to 537 in Q3 FY2021
Revenue contribution from the arthroplasty specialty increased to 40% as compared to 17% in the previous quarter and ARPOB also increased to Rs. 33,225 as compared to Rs. 26,660 in Q3 FY21.
This is in line with our previously communicated guidance that although surgeries have been postponed due to the pandemic, we can expect a quick reversion to a normalized number of orthopedic surgeries. However, the Covid-19 situation in the current quarter has deteriorated further and the Shalby hospital group continues to serve its local hospital communities to the best of its abilities.
With this context in mind, Shalby delivered total income of Rs. 1,440 million, an increase of 9.3% on q-o-q basis and 24.1% on y-o-y. EBITDA was Rs. 346 million, an increase of 7.0% on q-o-q and 167.8% on y-o-y, with margins of 24%.
As expected, there was an increase in materials and consumables expenses driven by the increase in number of surgeries, however this was offset by a reduction in other operative expenses. Overall, net profit was Rs. 110 million with margins of 7.7%. Our balance sheet remains robust with a net cash position of Rs. 636 million at the end of March 2021 and it gives us the ability to fund our strategic growth plans.
We all are going through one of the most challenging times with the ongoing second wave of the pandemic, which is turning out to be more severe than expected. Across the Shalby hospital group, we have increased the allocation of Covid-19 beds and our dedicated team of doctors, support staff stands united to serve our patients with full commitment in these trying times.”